Capstone Investment Advisors
TRVI icon

Capstone Investment Advisors’s Trevi Therapeutics TRVI Stock Holding History

Capstone Investment Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-73,287
Closed -$671K – 2054
2025
Q3 		$671K Buy
+73,287
New +$550K ﹤0.01% 1203

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Capstone Investment Advisors's TRVI Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Trevi Therapeutics (TRVI) in Q4 2025, closing a stake of 73,287 shares — an estimated $671K sold.

Capstone Investment Advisors first reported a position in TRVI in Q3 2025 and held it in 1 quarter. The position peaked at $671K in Q3 2025. 184 funds tracked by Wall St. Rank hold TRVI as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Trevi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 73,287 Trevi Therapeutics shares in Q4 2025, an estimated $671K.
  • Capstone Investment Advisors first reported a position in Trevi Therapeutics in Q3 2025 and held it in 1 quarter.
  • Capstone Investment Advisors's Trevi Therapeutics position peaked at $671K in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.